Morgan Stanley Call 750 LLY 21.03.../ DE000ME8QRU0 /
9/6/2024 2:09:46 PM | Chg.-0.06 | Bid5:05:16 PM | Ask5:05:16 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.70EUR | -1.60% | 3.60 Bid Size: 15,000 |
3.75 Ask Size: 15,000 |
ELI LILLY | 750.00 - | 3/21/2025 | Call |
Newsfile Corp
8/28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
8/27
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire
8/21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
8/21
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
8/14
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire
8/14
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
8/8
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
8/6
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
8/6
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire
8/2
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire
8/1
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
8/1
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives